Market Overview

Bank of America Initiates Coverage on Jazz Pharmaceuticals Positive Outlook

Share:
Related JAZZ
How Big Pharma Uses Charity Programs To Cover Drug Price Hikes
Jazz Pharma On Track To Report Top-Line, Late-Stage Results Of JZP-110 By December

In a report published Monday, Bank of America initiated coverage on Jazz Pharmaceuticals (NASDAQ: JAZZ) with a Buy rating and $74 price objective.

Bank of America reported that, “We initiated coverage of Jazz with a Buy rating and $74 PO, which is based on a sum-of-the-parts DCF analysis and does not require multiple expansion. We like Jazz's focus on areas with strong growth potential and franchise durability, and we expect strong sales and EPS growth over the next several years driven by Xyrem and Erwinaze.”

Jazz Pharmaceuticals closed at $56.03 on Monday.

Latest Ratings for JAZZ

DateFirmActionFromTo
May 2016Mizuho SecuritiesUpgradesNeutralBuy
Apr 2016SunTrust Robinson HumphreyUpgradesNeutralBuy
Feb 2016Stifel NicolausMaintainsBuy

View More Analyst Ratings for JAZZ
View the Latest Analyst Ratings

Posted-In: Bank of AmericaAnalyst Color Initiation Analyst Ratings

 

Related Articles (JAZZ)

View Comments and Join the Discussion!